Literature DB >> 14972652

Late onset Tay-Sachs disease in mice with targeted disruption of the Hexa gene: behavioral changes and pathology of the central nervous system.

Elena I Miklyaeva1, Weijia Dong, Alexandre Bureau, Roya Fattahie, Yongqin Xu, Meng Su, Gordon H Fick, Jing-Qi Huang, Suleiman Igdoura, Nobuo Hanai, Roy A Gravel.   

Abstract

Tay-Sachs disease is an autosomal recessive neurodegenerative disease resulting from a block in the hydrolysis of GM2 ganglioside, an intermediate in ganglioside catabolism. The mouse model of Tay-Sachs disease (Hexa -/-) has been described as behaviorally indistinguishable from wild type until at least 1 year of age due to a sialidase-mediated bypass of the metabolic defect that reduces the rate of GM2 ganglioside accumulation. In this study, we have followed our mouse model to over 2 years of age and have documented a significant disease phenotype that is reminiscent of the late onset, chronic form of human Tay-Sachs disease. Onset occurs at 11-12 months of age and progresses slowly, in parallel with increasing storage of GM2 ganglioside. The disease is characterized by hind limb spasticity, weight loss, tremors, abnormal posture with lordosis, possible visual impairment, and, late in the disease, muscle weakness, clasping of the limbs, and myoclonic twitches of the head. Immunodetection of GM2 ganglioside showed that storage varies widely in different regions, but is most intense in pyriform cortex, hippocampus (CA3 field, subiculum), amygdala, hypothalamus (paraventricular supraoptic, ventromedial and arcuate nuclei, and mammilary body), and the somatosensory cortex (layer V) in 1- to 2-year-old mutant mice. We suggest that the Tay-Sachs mouse model is a phenotypically valid model of disease and may provide for a reliable indicator of the impact of therapeutic strategies, in particular geared to the late onset, chronic form of human Tay-Sachs disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14972652     DOI: 10.1016/j.brainres.2003.11.067

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

Review 1.  The GM1 and GM2 Gangliosidoses: Natural History and Progress toward Therapy.

Authors:  Debra S Regier; Richard L Proia; Alessandra D'Azzo; Cynthia J Tifft
Journal:  Pediatr Endocrinol Rev       Date:  2016-06

2.  Gene transfer corrects acute GM2 gangliosidosis--potential therapeutic contribution of perivascular enzyme flow.

Authors:  M Begoña Cachón-González; Susan Z Wang; Rosamund McNair; Josephine Bradley; David Lunn; Robin Ziegler; Seng H Cheng; Timothy M Cox
Journal:  Mol Ther       Date:  2012-03-27       Impact factor: 11.454

3.  Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates.

Authors:  Jagdeep S Walia; Naderah Altaleb; Alexander Bello; Christa Kruck; Matthew C LaFave; Gaurav K Varshney; Shawn M Burgess; Biswajit Chowdhury; David Hurlbut; Richard Hemming; Gary P Kobinger; Barbara Triggs-Raine
Journal:  Mol Ther       Date:  2014-12-17       Impact factor: 11.454

4.  Isolation, sequence identification and tissue expression profiles of 3 novel porcine genes: ASPA, NAGA, and HEXA.

Authors:  Xianghua Shu; Yonggang Liu; Liangyu Yang; Chunlian Song; Jiafa Hou
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

Review 5.  Sphingolipids and membrane biology as determined from genetic models.

Authors:  Raghavendra Pralhada Rao; Jairaj K Acharya
Journal:  Prostaglandins Other Lipid Mediat       Date:  2007-10-13       Impact factor: 3.072

6.  Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice.

Authors:  Lionel M Igaz; Linda K Kwong; Edward B Lee; Alice Chen-Plotkin; Eric Swanson; Travis Unger; Joe Malunda; Yan Xu; Matthew J Winton; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Clin Invest       Date:  2011-01-04       Impact factor: 14.808

7.  Mice doubly-deficient in lysosomal hexosaminidase A and neuraminidase 4 show epileptic crises and rapid neuronal loss.

Authors:  Volkan Seyrantepe; Pablo Lema; Aurore Caqueret; Larbi Dridi; Samar Bel Hadj; Stephane Carpentier; Francine Boucher; Thierry Levade; Lionel Carmant; Roy A Gravel; Edith Hamel; Pascal Vachon; Graziella Di Cristo; Jacques L Michaud; Carlos R Morales; Alexey V Pshezhetsky
Journal:  PLoS Genet       Date:  2010-09-16       Impact factor: 5.917

8.  Mice, double deficient in lysosomal serine carboxypeptidases Scpep1 and Cathepsin A develop the hyperproliferative vesicular corneal dystrophy and hypertrophic skin thickenings.

Authors:  Xuefang Pan; Yanting Wang; Torben Lübke; Aleksander Hinek; Alexey V Pshezhetsky
Journal:  PLoS One       Date:  2017-02-24       Impact factor: 3.240

9.  The GM2 gangliosidoses: Unlocking the mysteries of pathogenesis and treatment.

Authors:  Camilo Toro; Mosufa Zainab; Cynthia J Tifft
Journal:  Neurosci Lett       Date:  2021-08-25       Impact factor: 3.046

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.